Results of the Clinical Study of the Sinopharm Vaccine

The Ministry of Health and the National Institute of Health report that the Sinopharm vaccine has been approved by the World Health Organization (WHO) for use against the COVID-19 pandemic.

The Phase 3 clinical study of the Sinopharm vaccine showed that the second dose of the vaccine is 79% effective against symptomatic SARS-CoV-2 infection 14 days after the second dose. Additionally, the efficacy in preventing hospitalization is also reported to be 79%.